Cancer Cells Hijack DNA Repair Networks to Stay Alive, Pitt Study Shows
PITTSBURGH, Nov. 8, 2016
– Research by scientists at the University of Pittsburgh Cancer Institute
(UPCI) has revealed how cancer cells hijack DNA repair pathways to prevent telomeres, the endcaps of chromosomes, from shortening, thus allowing the tumor to spread. The findings are published today in the journal Cell Reports
The moment a cell is formed, a countdown clock starts ticking that determines how long the cell can live. The clock is the telomere, a series of repeating DNA letters at the ends of each chromosome in the cell.
However, cancer cells cleverly hijack this telomere clock, resetting it and lengthening the telomere every time it shortens. This leads the cell into thinking that it is still young and can divide, spreading the tumor.
Most cancers do this by increasing the activity of an enzyme called telomerase which lengthens telomeres. But approximately 15 percent of cancers use a different mechanism for resetting the clock, called alternative lengthening of telomeres (ALT).
Growing evidence also suggests that tumors that activate the ALT pathway are aggressive and more resistant to treatment. Although ALT was identified close to two decades ago, identifying how this mechanism works has proved elusive.
“Identifying the parts that the cancer cell tweaks to reset the countdown timer could provide targets for developing new cancer drugs or making existing ones more effective,” said senior author Roderick O’Sullivan, Ph.D., assistant professor of pharmacology and chemical biology at Pitt’s School of Medicine
and a member of UPCI.
O’Sullivan and his team tackled this problem by using a recently developed technique called proximity dependent biotinylation (BioID), which allowed them to quickly identify proteins that were physically close to, and hence potentially associated with, telomere lengthening in cancer cells.
When comparing cancer cells in which either telomerase or ALT were active, the BioID technique identified 139 proteins that were unique to ALT-activated cells. As the research team took a closer look, one enzyme, DNA polymerase η (Polη), took them by surprise.
“We expected to see DNA repair proteins, but seeing Polη was really unexpected as it was known to be activated only in cells that were damaged by UV light, which we did not use in our experiments. Its role in the ALT pathway is completely independent of how we think of it normally,” said O’Sullivan. Knowing the molecular players in the ALT pathway opens up a whole new area of research and many potential drug targets, according to O’Sullivan.
Laura Garcia-Exposito, Ph.D., a postdoctoral fellow in O’Sullivan’s lab, and Elodie Bournique, a graduate student in the laboratory of Dr. Jean-Sébastien Hoffmann at the Cancer Research Center of Toulouse, France, are the co-first authors of the study.
Other study authors include Arindam Bose, Ph.D., Simon C. Watkins, Ph.D., Patricia Opresko, Ph.D., Callen Wallace and Justin L. Roncaioli, all of the University of Pittsburgh; Valérie Bergoglio, Ph.D., and Jean-Sébastien Hoffmann Ph.D., of the Cancer Research Center at the University of Toulouse; Sufang Zhang, Ph.D., and Marietta Lee Ph.D., of New York Medical College.
This research was funded by grants from the Competitive Medical Research Fund and Stimulating Pittsburgh Research in Geroscience at the University of Pittsburgh, National Institutes of Health grants
ES022944, P30CA047904, 1S10OD019973-O1; and INCa-PLBIO 2016, ANR PRC 2016, Labex Toucan, and La Ligue contre le Cancer.